1. Market Research
  2. > Biotechnology
  3. > Biopharmaceutical Market Trends
  4. > Global Oncology Biosimilars Market 2016-2020

Global Oncology Biosimilars Market 2016-2020

  • February 2016
  • -
  • Infiniti Research Limited
  • -
  • 109 pages

About Oncology Biosimilars

Cancer represents a huge burden on healthcare systems worldwide due to the high cost of treatment therapeutics. The patent expiry of many cancer therapeutics enables the entry of biosimilars into the market. Biosimilars are being incorporated into oncology treatment practices in the supportive care setting. Biosimilars are synthesized with the use of biologic components such as monoclonal antibodies, proteins, hormones, nucleic acids, colony stimulating factors, interleukins, and enzymes.

Technavio’s analysts forecast the global oncology biosimilars market to grow at a CAGR of 31.76% during the period 2016-2020.

Covered in this report
The report covers the present scenario and the growth prospects of the global oncology biosimilars market for the period 2016-2020. To calculate the market size, the report considers revenue generated from the sales of biosimilars used to treat cancer.


The market is divided into the following segments based on geography:
- Americas
- APAC
- EMEA

Technavio's report, Global Oncology Biosimilars Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the Key vendorsoperating in this market.

Key vendors
- Biocon
- Celltrion
- Dr. Reddy's Laboratories
- F. Hoffmann-La Roche
- Hospira
- Mylan
- Sandoz


Other prominent vendors
- AbbVie
- Allergan
- Amgen
- AstraZeneca
- Baxter
- Biogen
- BioXpress Therapeutics
- Boehringer Ingelheim
- Cipla
- Coherus BioSciences
- Coherus BioSciences
- Daiichi Sankyo
- Emcure Pharmaceuticals
- GlaxoSmithKline (GSK)
- Intas Pharmaceuticals
- Merck
- Pfizer
- Sanofi
- 3SBio
- Wockhardt

Market driver
- Rise in number of patent expiries
- For a full, detailed list, view our report

Market challenge
- Risks related to failure of drugs in the market
- For a full, detailed list, view our report

Market trend
- Emergence of biosimilars
- For a full, detailed list, view our report

Key questions answered in this report
- What will the market size be in 2020 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

Table Of Contents

Global Oncology Biosimilars Market 2016-2020
PART 01: Executive summary
- Highlights
PART 02: Scope of the report
- Market overview
- Top-vendor offerings
PART 03: Market research methodology
- Research methodology
- Economic indicators
PART 04: Introduction
- Key market highlights
PART 05: Overview of cancer
- Epidemiology
- Economic burden of cancer
PART 06: Biosimilars industry
- Comparison between biosimilars and generic small molecules
- Factors influencing biologics and biosimilars
- Biosimilars: business and pricing strategy
- Factors affecting the uptake of biosimilars
- Biosimilar opportunities
- Growth of biosimilars 2014- 2020
- Market penetration of originators and biosimilars in different regions
- Current and future trends in global oncology biosimilars market
- Challenges for new entrants
PART 07: Global pharmaceutical market
- Market size and forecast
- Global biosimilars market
PART 08: Market landscape
- Market overview
- Market size and forecast
- Five forces analysis
PART 09: Market segmentation by end-user
- Hospitals
- Retail pharmacies
PART 10: Market segmentation by application
- Cancer treatment drugs
- Supportive care drugs
PART 11: Geographical segmentation
- Global oncology biosimilar drugs market by geographical segmentation 2015-2020
- Oncology biosimilars market in EMEA
- Oncology biosimilars market in APAC
- Oncology biosimilars market in Americas
PART 12: Key leading regions
- US
- Europe
- Japan
- India
- China
PART 13: Market drivers
- Rise in number of patent expiries
- Increase in prevalence of cancer
- Growing aging population
- Promising drug pipeline
- Need for cost-effective treatment
- Favorable government regulations
PART 14: Impact of drivers
PART 15: Market challenges
- Risks related to failure of drugs in market
- Multiple manufacturing complexities
- Reluctance among physicians to prescribe biosimilar products
- Complicated regulatory process
- Limited availability of biosimilar products
- Risk of side effects
PART 16: Impact of drivers and challenges
PART 17: Market trends
- Emergence of biosimilars
- Outsourcing of biosimilar manufacturing activities
- Rising number of strategic collaborations
- Increase in cancer awareness
- Rise in RandD
PART 18: Vendor landscape
- Competitive scenario
- Biocon
- Celltrion
- Dr. Reddy's Laboratories
- F Hoffmann-La Roche
- Hospira
- Mylan
- Sandoz
- Other prominent vendors
PART 19: Appendix
- List of abbreviations
PART 20: Explore Technavio

List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Global biosimilars and oncology biosimilars market 2015
Exhibit 03: Cancer burden in European Union (EU)
Exhibit 04: Global incidence of cancer 2015
Exhibit 05: Global mortality of cancer type 2015
Exhibit 06: Estimated numbers of cancer survivors by age in US 2014
Exhibit 07: Definition of biosimilars in different regions
Exhibit 08: Comparison between biosimilars and generic small molecules
Exhibit 09: Factors influencing biologics and biosimilars
Exhibit 10: Impact of biosimilars cost savings on various sectors
Exhibit 11: Factors affecting success of biosimilars
Exhibit 12: Biosimilars industry: Point-of-view
Exhibit 13: Factors affecting the uptake of biosimilars
Exhibit 14: Strategic factors for new entrant
Exhibit 15: Growth of biosimilars
Exhibit 16: Share of biosimilars in recombinant drugs sales in major markets 2014
Exhibit 17: Trends in global oncology biosimilars market
Exhibit 18: Challenges for new entrants
Exhibit 19: Global pharmaceutical market 2015-2020 ($ trillions)
Exhibit 20: Global biosimilars market 2015-2020 ($ billions)
Exhibit 21: Number of approved biosimilars in regulated and semi-regulated markets
Exhibit 22: Global pharmaceutical, biosimilars, and oncology biosimilars market 2015 ($ billions)
Exhibit 23: Global oncology biosimilars market 2015-2020 ($ billions)
Exhibit 24: Global oncology biosimilars market overview
Exhibit 25: Five forces analysis
Exhibit 26: Oncology biosimilars market segmentation by end-user 2014
Exhibit 27: Global oncology biosimilars segmentation by application
Exhibit 28: Oncology biosimilars by application
Exhibit 29: Global oncology biosimilars market by geographical segmentation 2015
Exhibit 30: Global oncology biosimilars market revenue by geography 2015-2020 ($ billions)
Exhibit 31: Oncology biosimilars market in EMEA 2015-2020 ($ billions)
Exhibit 32: Oncology biosimilars market in APAC 2015-2020 ($ billions)
Exhibit 33: Oncology biosimilars market in Americas 2015-2020 ($ billions)
Exhibit 34: Global oncology biosimilars market: YoY revenue and growth based on geography 2015-2020 ($ billions)
Exhibit 35: Key leading regions
Exhibit 36: Pharmaceutical RandD expenditure in US 2010-2015 ($ billions)
Exhibit 37: Approvals of biologicals versus biosimilars via PHSA
Exhibit 38: Approval process for biosimilars in US
Exhibit 39: Benefits of biosimilars to US healthcare system
Exhibit 40: Role of stake holders
Exhibit 41: SWOT analysis
Exhibit 42: Oncology biosimilars approved by EMA in Europe
Exhibit 43: Guidelines for biosimilars in EU
Exhibit 44: Time line of biosimilars in Europe
Exhibit 45: Key stake holders
Exhibit 46: Key drivers and restraints
Exhibit 47: Biosimilar industry challenges in Europe
Exhibit 48: SWOT analysis
Exhibit 49: Biosimilars approved by PMDA in Japan
Exhibit 50: Review process for biosimilars in Japan
Exhibit 51: Drivers and challenges in oncology biosimilars market in Japan
Exhibit 52: SWOT analysis
Exhibit 53: Biosimilars approved in India
Exhibit 54: Timeline for development of biosimilars in India
Exhibit 55: Challenges and strategies
Exhibit 56: Major domestic and international vendors operating in India
Exhibit 57: Drivers and challenges
Exhibit 58: SWOT analysis
Exhibit 59: Top domestic and international vendors operating in China
Exhibit 60: Drivers and challenges
Exhibit 61: SWOT analysis
Exhibit 62: Patent expiries of oncology biologics in US and EU 2020
Exhibit 63: Global incidence of cancer 2015 and 2020
Exhibit 64: Impact of drivers
Exhibit 65: Impact of drivers and challenges
Exhibit 66: Global competitive landscape 2015
Exhibit 67: Biocon: Key takeaways
Exhibit 68: Celltrion: Key takeaways
Exhibit 69: Dr. Reddy's Laboratories: Key takeaways
Exhibit 70: F. Hoffmann-La: Key takeaways
Exhibit 71: Hospira: Key takeaways
Exhibit 72: Mylan: Key takeaways
Exhibit 73: Sandoz: Key takeaways

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Remicade Biosimilar Market: By Type (Recombinant Non-Glycosylated Protein, Others), By Technology (MAb, rDNA, Others), By Service (Contract Research, CRAMS,Others), By Application (Blood Disorders, Oncology Diseases, Others), By Region-Forecast (2016-2021

Remicade Biosimilar Market: By Type (Recombinant Non-Glycosylated Protein, Others), By Technology (MAb, rDNA, Others), By Service (Contract Research, CRAMS,Others), By Application (Blood Disorders, Oncology Diseases, Others), By Region-Forecast (2016-2021

  • $ 5250
  • Industry report
  • September 2016
  • by Industry ARC

Globally, development of efficient and advance technology, higher expiration patent, rise in the awareness among people regarding remicade biosimilar, increasing government initiative across the globe, ...

Biosimilar - Global Market Outlook (2016-2022)

Biosimilar - Global Market Outlook (2016-2022)

  • $ 4157
  • Industry report
  • September 2016
  • by Stratistics MRC

According to Stratistics MRC, the Global Biosimilars market is estimated to be $3.5 billion in 2015 with a CAGR of 23.8% is poised to reach $15.6 billion by 2022. High end adoption of off patented drugs ...

Insulin Biosimilars - Global Market Outlook (2016-2022)

Insulin Biosimilars - Global Market Outlook (2016-2022)

  • $ 4157
  • Industry report
  • October 2016
  • by Stratistics MRC

According to Stratistics MRC, the Global Insulin Biosimilars market is accounted for $xx million in 2015 and is expected to reach $xx million by 2022 growing at a CAGR of xx% from 2015 to 2022. Growing ...


Download Unlimited Documents from Trusted Public Sources

Biosimilar Industry in Europe

  • November 2016
    42 pages
  • Biosimilar  

  • Europe  

View report >

Pathology Statistics in Canada

  • October 2016
    2 pages
  • Biosimilar  

  • Canada  

    North America  

View report >

Global Breast Cancer Statistics

  • October 2016
    2 pages
  • Breast Cancer  

    Biosimilar  

  • Europe  

    World  

    Hungary  

View report >

Bioprocessing Industry

3 months ago

Biosimilar Statistics

3 months ago

Biosimilar Statistics

3 months ago

Related Market Segments :

Biosimilar

ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.